HCM | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 7%

Liquidity 74%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.32%

1 Month

-8.76%

3 Months

-1.35%

6 Months

-14.03%

1 Year

-13.55%

2 Year

-7.05%

Key data

Stock price

$13.85

P/E Ratio

0.00

DAY RANGE

$13.68 - $14.01

EPS

-$0.69

52 WEEK RANGE

$11.50 - $19.50

52 WEEK CHANGE

-$16.21

MARKET CAP

3.041 B

YIELD

N/A

SHARES OUTSTANDING

174.272 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-30-2025

BETA

-0.19

PUBLIC FLOAT

AVERAGE 10 VOLUME

$23,136

AVERAGE 30 VOLUME

$26,019

Company detail

CEO: Wei G. Su
Region: US
Website: hutch-med.com
Employees: 1,760
IPO year: 2016

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and gastric cancer (GC) In addition, it develops Tazemetostat, an inhibitors of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients.

HCM - HUTCHMED (China) Ltd